undamentalytics Newsletter
Sign in

Cryo Cell International Inc (CCEL) stock

Add to watchlist

Add holding +

NYSE: CCEL NYSE Health Care Services

C+ Fundamentals grade

Cryo Cell International Inc is a US-listed company in the health care services industry. Its financial year ends in November.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$9.8

Cash-flow model

Base case. Range ~$7.2–$13 across our lower- and higher-growth cases (-3%–7% a year).

Price vs value

Undervalued

The price is below our entire value range; our base value is 84% above it.

Price used: $5.35, November 2, 2026

Cryo Cell International Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds6 adding, 3 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Cryo Cell International files

Where Cryo Cell International stands after its latest 10-Q

Revenue for the twelve months to August 2026 was $31m, down 2.0% on a year earlier, a smaller fall than the 2.7% decline a quarter earlier. That puts it 30 of 36 for growth among the health care services companies we cover. Free-cash-flow margin fell to 14.9% from 19.5% a year earlier. Operating margin narrowed to 0.6% from 13.6%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 1 of our 5 financial-health checks. Our cash-flow model value is $10.48 a share.

Source: 10-Q filed October 9, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Cryo Cell International Inc's trailing-twelve-month revenue fell 2.0% year on year, with a free-cash-flow margin of 14.9%. Where it stands out: gross margin of 78.5% ranks 1 of 27 health care services companies we cover. Where it lags: days sales outstanding of 80 days ranks 28 of 31 health care services companies we cover.

Our discounted-cash-flow model values the business at ~$9.8 per share in the base case (~$7.2–$13 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 24.8% while net income fell 310.8%: a 286pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Priced below our value. The share price of $5.35 is 84% below our value per share of $10.
  • Shrinking share count. Diluted shares fell 1.4% in a year, so each share owns more of the business.

Things to watch

  • Revenue shrinking. Revenue fell 2.0% over the last 12 months.
  • Margins narrowing. Operating margin is down 13.0 points on a year ago.
  • Volatile shares. Over the past year the shares showed annualised volatility of 75% and a beta of 0.5 against the S&P 500.
  • Below peers: days sales outstanding. Days sales outstanding of 80 days ranks 28 of 31 health care services companies we cover (median 39 days).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.
  • Earnings expected to fall. The consensus expects earnings per share to fall 82% next year.

Latest results: FY2026 Q3

Filed October 9, 2026
Earnings per share
$0.17 against an average estimate of $0.03: beat by 451.7%
Revenue
$8m, down 0.0% on a year earlier

Cryo Cell International's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.7%
  • 1 week+6.8%
  • 1 month+34.1%
  • This year+55.5%
  • 1 year+18.6%
  • 5 years-46.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$31.1M
Operating margin
0.6%
Net margin
-6.2%
EPS (TTM, diluted)
$-0.24

Growth

Revenue growth
−2.0%
Change in growth rate
+0.7 pts
Share count change
−1.4%

Cash

Free cash flow (TTM)
$4.7M
FCF margin
14.9%
Stock pay % of revenue
1.1%

Earnings

Last results
October 17, 2024

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Shareholder vote
  2. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Cryo Cell International Inc valuation models and calculator

What the price is pricing in

The share price implies cash flow shrinking about 9.8% a year for five years.That is slower than the 1.5% a year revenue growth Cryo Cell International has delivered.

  • Priced in-9.8%
  • Last 12 months-2.0%
  • 3 years a year-0.1%
  • 5 years a year1.5%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($5.00, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Buy12-month view
12-month price target
~$9.8
Price used
$5.00close November 3, 2026
Implied change
▲ +97%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Cryo Cell International Inc's free cash flow after stock-based pay with after-tax interest added back ($5.3M, FY2026 Q3 TTM), growing -2.3% and 1% in the next two years (forecasts, guidance and its record), then back to 2% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$7.2–~$13 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Cryo Cell International Inc's free cash flow after stock-based pay ( $5.3M, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Cryo Cell International Inc as an operating company, with every model that fits that kind of business. Cost of equity 7.7%: the 10-year Treasury yield (4.9%) plus a beta of 0.61 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$9.8 ~$7.2–$13 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: book value or earnings not available
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$9.8 ~$7.2–$13 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Cryo Cell International Inc with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −26%
  • Revenue growth 5 points higher ▲ +35%
  • Free-cash-flow margin 1 point lower ▼ −5%
  • Last year's free-cash-flow margin change, if it persists ▼ −19%
  • Discount rate 1 point higher ▼ −15%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $9$12$17$23$31$41
8.5% $7$9$13$17$22$30
10% $5$7$10$13$17$23

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$2.65$3.41$6.46$5.87$6.06$6.02$9.93$3.99$4.89$8.15$4.30$5.35
Market value$26m$28m$49m$44m$51m$49m$83m$34m$41m$67m$35m$43m
+ Net debt (− = net cash)−$4m$8m$3m$10m$6m−$1m−$4m$9m$9m$11m$10m$7m
Enterprise value$22m$36m$52m$54m$56m$48m$79m$43m$50m$78m$45m$50m
Multiples
Price / sales 1.2x1.2x1.9x1.5x1.6x1.6x2.9x1.1x1.3x2.1x1.1x1.4x
Price / earnings 3.2x—21.4x—22.2x13.5x39.9x12.2x—166.6x——
Price / free cash flow 5.5x6.0x8.8x9.0x9.0x5.9x13.6x—19.6x18.6x6.6x9.2x
EV / EBITDA 7.2x61.2x10.2x9.8x10.3x5.9x15.5x7.8x—18.8x30.7x47.7x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

73 /100

Strong moat

How hard Cryo Cell International's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Cash operating profit has been a median 16.8% of total assets over 9 years.

  • Pricing power 19 / 20

    Gross margin has been a median 72.3%, moving by 3.5 percentage points (standard deviation) across 9 years.

  • Durability 4 / 20

    Operating margin has been a median 14.8%; its worst year was -39.5%.

  • Cash conversion 18 / 20

    Free cash flow was positive in 9 of 10 years, at a median 18.2% of revenue.

  • Discipline 18 / 20

    The diluted share count fell 3.8% over five years; stock-based pay has been a median 1.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (78 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.11 +145% $30m −5%
Next $0.02 −82% $28m −5%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −126.2% on 90 days ago. In the last 30 days, 1 analyst raised Cryo Cell International Inc's forecast and 0 cut it.

Consensus EPS forecast Cryo Cell International Inc, last 90 days
−$0.60 −$0.40 −$0.20 $0.00 $0.20 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.42 Current fiscal year, 60 days ago: −$0.42 Current fiscal year, 30 days ago: $0.08 Current fiscal year, 7 days ago: $0.08 Current fiscal year, Now: $0.11 $0.11

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal year
90 days ago −$0.42
60 days ago −$0.42
30 days ago $0.08
7 days ago $0.08
Now $0.11

Earnings against estimates

Quarter toEstimateActualSurprise
Aug 2026 $0.03 $0.17 +451.7%
May 2026 $0.00 $0.07 0.0%
Feb 2026 −$0.02 $0.02 +195.0%
Nov 2025 −$0.09 −$0.47 −417.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 17, 2024

No numeric guidance in Cryo Cell International Inc's latest earnings release (filed October 17, 2024). Some companies give their outlook only on the earnings call.

How our valuation uses these forecasts

Our cash-flow model grows Cryo Cell International Inc's revenue by -2.3% next year and +1.0% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (-7.4%, weight 45%) and the company's own record (+2.0%, weight 55%) . How the weights are set.

Positioning

Short interest
0.1%
of tradable shares
Days to cover
0.53
at average volume
Short interest, 1 month
−22%
to October 15, 2026
Held by institutions
14%
of shares
Held by insiders
42.1%
of shares
Employees
72
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +18.6%

$4.51 on October 31, 2025 to $5.35

ThenNowEffect
Revenue (last 12 months) $32m $31m −2.0%
P/S multiple 1.2x 1.4x +19.3%
Share count 8m 8m +1.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +15.5%

$4.63 on November 3, 2023 to $5.35

ThenNowEffect
Revenue (last 12 months) $31m $31m −0.3%
P/S multiple 1.2x 1.4x +11.3%
Share count 8m 8m +4.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CCEL+51%−59%+36%+33%−51%+56%
Industry peers (median)−3%−25%+6%−6%−6%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CCEL58%8%42%42%33%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CCEL−21%−60%−41%−38%−58%−29%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 76% from September 2, 2021 to March 28, 2023. Getting back needed a 319% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.89 – $5.35
From 52-week high
0.0%
vs 50-day average
+23.8%
vs 200-day average
+45.0%
Volatility (1 year)
75%
Beta vs S&P 500
0.49

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±3.0%
After a week
5 up, 7 down
typical move ±4.7%
After a month
5 up, 7 down
typical move ±10.5%
Results releasedNext dayS&P 500 next day5 days21 days
October 17, 2024 +1.4% +0.4% −0.8% +38.9%
February 24, 2022 −0.5% +3.7% −1.8% −7.3%
October 15, 2021 −2.3% +1.1% −3.0% −4.6%
July 19, 2021 −0.1% −0.1% −1.3% +0.3%
April 16, 2021 −1.8% −0.2% +2.4% −9.0%
February 25, 2021 +15.6% −2.9% +15.6% +4.0%
October 19, 2020 +2.9% −1.1% +10.4% +8.6%
July 13, 2020 +5.5% +0.4% +16.1% +27.6%
May 6, 2020 +1.3% +0.5% −1.3% −3.5%
March 2, 2020 +0.1% +1.3% −0.1% −11.2%
October 17, 2019 +2.8% −0.1% −2.9% −4.7%
July 25, 2019 −1.2% +0.2% +0.9% −6.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Cryo Cell International Inc in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Cryo Cell International Inc
$31M $31.5M $32M $32.5M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $31.3M Revenue (TTM), FY24 Q1: $31.4M Revenue (TTM), FY24 Q2: $31.6M Revenue (TTM), FY24 Q3: $31.8M Revenue (TTM), FY24 Q4: $32M Revenue (TTM), FY25 Q1: $32.1M Revenue (TTM), FY25 Q2: $32M Revenue (TTM), FY25 Q3: $31.7M Revenue (TTM), FY25 Q4: $31.6M Revenue (TTM), FY26 Q1: $31.3M Revenue (TTM), FY26 Q2: $31.1M Revenue (TTM), FY26 Q3: $31.1M $31.1M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $31.3M
FY24 Q1 $31.4M
FY24 Q2 $31.6M
FY24 Q3 $31.8M
FY24 Q4 $32M
FY25 Q1 $32.1M
FY25 Q2 $32M
FY25 Q3 $31.7M
FY25 Q4 $31.6M
FY26 Q1 $31.3M
FY26 Q2 $31.1M
FY26 Q3 $31.1M
Revenue growth, TTM YoY Cryo Cell International Inc
-4% -2% 0% 2% 4% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 3.3% Revenue growth, TTM YoY, FY24 Q1: 1.5% Revenue growth, TTM YoY, FY24 Q2: 1.9% Revenue growth, TTM YoY, FY24 Q3: 1.9% Revenue growth, TTM YoY, FY24 Q4: 2.0% Revenue growth, TTM YoY, FY25 Q1: 2.3% Revenue growth, TTM YoY, FY25 Q2: 1.1% Revenue growth, TTM YoY, FY25 Q3: -0.3% Revenue growth, TTM YoY, FY25 Q4: -1.3% Revenue growth, TTM YoY, FY26 Q1: -2.6% Revenue growth, TTM YoY, FY26 Q2: -2.7% Revenue growth, TTM YoY, FY26 Q3: -2.0% -2.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 3.3%
FY24 Q1 1.5%
FY24 Q2 1.9%
FY24 Q3 1.9%
FY24 Q4 2.0%
FY25 Q1 2.3%
FY25 Q2 1.1%
FY25 Q3 -0.3%
FY25 Q4 -1.3%
FY26 Q1 -2.6%
FY26 Q2 -2.7%
FY26 Q3 -2.0%
Operating margin (TTM) Cryo Cell International Inc
-60% -40% -20% 0% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -39.3% Operating margin (TTM), FY24 Q1: -42.0% Operating margin (TTM), FY24 Q2: -40.5% Operating margin (TTM), FY24 Q3: -39.5% Operating margin (TTM), FY24 Q4: 10.9% Operating margin (TTM), FY25 Q1: 11.6% Operating margin (TTM), FY25 Q2: 11.9% Operating margin (TTM), FY25 Q3: 13.6% Operating margin (TTM), FY25 Q4: 1.5% Operating margin (TTM), FY26 Q1: 0.6% Operating margin (TTM), FY26 Q2: -0.3% Operating margin (TTM), FY26 Q3: 0.6% 0.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -39.3%
FY24 Q1 -42.0%
FY24 Q2 -40.5%
FY24 Q3 -39.5%
FY24 Q4 10.9%
FY25 Q1 11.6%
FY25 Q2 11.9%
FY25 Q3 13.6%
FY25 Q4 1.5%
FY26 Q1 0.6%
FY26 Q2 -0.3%
FY26 Q3 0.6%
FCF margin (TTM) Cryo Cell International Inc
-10% 0% 10% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 6.6% FCF margin (TTM), FY24 Q1: -0.0% FCF margin (TTM), FY24 Q2: -1.6% FCF margin (TTM), FY24 Q3: 9.7% FCF margin (TTM), FY24 Q4: 11.3% FCF margin (TTM), FY25 Q1: 16.6% FCF margin (TTM), FY25 Q2: 18.6% FCF margin (TTM), FY25 Q3: 19.5% FCF margin (TTM), FY25 Q4: 16.6% FCF margin (TTM), FY26 Q1: 15.8% FCF margin (TTM), FY26 Q2: 19.6% FCF margin (TTM), FY26 Q3: 14.9% 14.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 6.6%
FY24 Q1 -0.0%
FY24 Q2 -1.6%
FY24 Q3 9.7%
FY24 Q4 11.3%
FY25 Q1 16.6%
FY25 Q2 18.6%
FY25 Q3 19.5%
FY25 Q4 16.6%
FY26 Q1 15.8%
FY26 Q2 19.6%
FY26 Q3 14.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Nov 2010 2011 Nov 2011 2012 Nov 2012 2013 Nov 2013 2014 Nov 2014 2015 Nov 2015 2016 Nov 2016 2017 Nov 2017 2018 Nov 2018 2019 Nov 2019 2020 Nov 2020 2021 Nov 2021 2022 Nov 2022 2023 Nov 2023 2024 Nov 2024 2025 Nov 2025 LTM Aug 2026
Income
Revenue 18 18 18 19 20 21 23 25 29 32 31 29 30 31 32 32 31
Gross profit — — — — — — — 19 21 22 21 20 22 23 24 24 24
EBITDA 4 0 −2 2 2 3 1 5 6 5 8 5 6 −11 4 1 1
Operating income 3 −0 −2 2 2 3 0 5 5 5 8 4 4 −12 3 0 0
Net income 3 −2 −6 0 1 8 −1 2 −1 2 4 2 3 −10 0 −2 −2
Diluted EPS $0.29 −$0.18 −$0.56 $0.00 $0.05 $0.83 −$0.16 $0.30 −$0.11 $0.27 $0.45 $0.25 $0.33 −$1.14 $0.05 −$0.30 −$0.24
Growth (year on year)
Revenue — +0.9% +0.3% +5.7% +6.0% +4.8% +9.7% +9.8% +15.1% +8.9% −2.1% −7.3% +5.0% +3.3% +2.0% −1.3% −2.0%
EBITDA — −97.7% — — +13.8% +40.5% −80.6% +773.4% +7.2% −0.8% +47.0% −37.0% +9.2% −297.4% — −64.8% −79.9%
Operating income — −108.3% — — +16.4% +48.1% −85.2% — +3.7% −2.4% +51.3% −47.6% +0.2% −405.7% — −86.1% −95.6%
Net income — −160.5% — — — +>999% −116.3% — −136.9% — +58.2% −42.5% +33.0% −443.6% — — —
Diluted EPS — −162.1% — — — +>999% −119.3% — −136.7% — +66.7% −44.4% +32.0% −445.5% — — —
Margins
Gross margin — — — — — — — 73.5% 70.8% 68.5% 69.0% 68.9% 71.0% 73.2% 75.2% 76.6% 78.5%
EBITDA margin 20.5% 0.5% −8.4% 10.0% 10.7% 14.3% 2.5% 20.2% 18.8% 17.2% 25.8% 17.5% 18.2% −34.8% 13.0% 4.6% 3.4%
Operating margin 18.8% −1.5% −9.5% 9.0% 9.8% 13.9% 1.9% 19.7% 17.8% 15.9% 24.6% 13.9% 13.3% −39.3% 10.9% 1.5% 0.6%
Net margin 19.5% −11.7% −35.1% 0.1% 2.8% 38.4% −5.7% 9.1% −2.9% 7.2% 11.6% 7.2% 9.1% −30.4% 1.3% −7.7% −6.2%
Free-cash-flow margin 10.9% 1.7% 1.3% 2.5% 7.1% 22.5% 20.1% 22.1% 16.7% 17.7% 26.9% 21.1% −11.9% 6.6% 11.3% 16.6% 14.9%
Cash flow
Cash from operations 2 1 0 1 2 5 5 6 5 6 8 8 9 9 6 5 5
Capital spending 0 1 0 0 0 0 0 0 0 1 0 2 12 7 2 0 0
Free cash flow 2 0 0 0 1 5 5 6 5 6 8 6 −4 2 4 5 5
Stock-based pay 0 0 1 0 0 1 2 1 0 0 1 0 0 1 1 0 0
Free cash flow after stock pay 2 −0 −1 0 1 4 3 5 4 5 8 6 −4 1 3 5 4
Balance sheet
Cash 8 6 3 4 3 4 3 6 6 7 10 8 2 0 1 0 1
Total debt 4 3 2 — 2 — 12 9 16 12 9 4 11 10 12 11 8
Net debt (negative = net cash) −5 −3 −0 −4 −1 −4 8 3 10 6 −1 −4 9 9 11 10 7
Diluted shares 12m 12m 11m 11m 10m 10m 8m 8m 7m 8m 8m 8m 8m 8m 8m 8m 8m
Returned to shareholders
Dividends — — — — — — — — — — — 0 8 0 2 3 0
Buybacks — — 2 1 3 3 11 0 — 1 — 0 2 1 1 0 —
Total returned — — 2 1 3 3 11 0 — 1 — 0 9 1 3 3 0

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 5 checks passed · August 31, 2026
What it owns · $62m
Short-term assets $13mLonger-term assets $49m
What it owes, and who funded it · $79m
Short-term liabilities $15mLonger-term liabilities $63mShareholders' equity $-16m
  • Short-term assets cover short-term liabilities $13m of assets due within a year against $15m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $13m short-term assets against $63m of longer-dated liabilities.
  • More cash than debt $1m of cash against $8m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $5m of operating cash flow against $8m of debt.
  • Operating profit covers interest at least five times over Operating income of $189,419 against $2m of interest.

From Cryo Cell International Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2025 Q4 TTM
Buybacks (TTM)
$169,502
Dividends (TTM)
$0
Returned to shareholders
65%
of free cash flow
Buybacks, last 3 fiscal years
$2.4M
Diluted share count
−1.4%
year over year
Total shareholder yield
0.4%
dividends 0.0% + buybacks 0.4% of market value
R&D spending
1.0%
of revenue
Sales & admin spending
60.6%
of revenue
Days sales outstanding
80 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated CCEL AMS HAO AHG RDGT NRC Median
Revenue, last 12 months $31m $30m $55m $14m $132m $140m $1.2bn
Revenue growth, last 12 months −2.0% 4.0% 67.1% −6.4% 10.2% −0.2% 7.3%
Revenue growth, 3-year average −0.1% 14.3% — — — −1.9% 11.3%
Revenue growth, latest quarter −0.0% 19.2% — — — 4.0% 8.5%
Gross margin 78.5% 17.1% 1.1% −0.1% 3.6% — 27.9%
Operating margin 0.6% −11.8% −17.6% −149.7% −1.4% 10.5% 2.3%
Operating margin, 3-year average −8.4% −8.5% — −44.4% — 19.1% 2.3%
Net margin −6.2% −5.8% −17.4% −135.0% −0.9% 4.0% 1.2%
Cash from operations / revenue 15.8% 17.6% −4.7% −92.5% −1.1% 21.1% 6.1%
Free-cash-flow margin 14.9% 11.6% −5.2% −92.5% −1.1% 15.5% 5.1%
Free-cash-flow margin, 3-year average 14.7% −14.8% — — — 12.5% 3.6%
Stock pay / revenue 1.1% 1.3% 0.2% 6.5% 8.6% 8.4% 1.1%
Change in share count −1.4% 0.4% >999% 153.5% 96.6% −5.2% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth -2.0% 7.3% 32 of 41
Change in growth rate Growth +0.7pp +1.1pp 23 of 41
Gross margin Profitability 78.5% 29.0% 1 of 27
Operating margin Profitability 0.6% 2.6% 23 of 40
Net margin Profitability -6.2% 1.2% 30 of 41
Free-cash-flow margin Cash generation 14.9% 5.1% 4 of 40
Stock pay as % of revenue Cash generation 1.2% 0.9% 21 of 35
Long-term debt as % of assets Balance sheet 13.2% 27.7% 8 of 31
Change in share count Balance sheet -1.4% 0.4% 13 of 39
Days sales outstanding Balance sheet 80 days 39 days 28 of 31

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to November 30, 2025
Segments
Line of business Revenue Share YoY
Umbilical Cord Blood and Cord Tissue Stem Cell Service $31.4M 99.4% ▼ 0.5%
Public Cord Blood Banking $129,513 0.4% ▼ 64.7%
Prepacytecb $54,104 0.2% ▼ 20.3%
Products and services
Line of business Revenue Share YoY
Processing and Storage Fees $31.4M 99.4% ▼ 0.5%
Public Banking $129,513 0.4% ▼ 64.7%
Products $54,104 0.2% ▼ 20.3%

From Cryo Cell International Inc's 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.8M
Institutions reporting
12
Shares held vs prior quarter
▲ 4.2%
Positions opened / closed
2 / 1

Top buyers and sellers, Q2 2026: 6 institutions bought and 3 sold ; the biggest buyer was FMR LLC (+20K shares) and the biggest seller Blackrock, Inc (−7,287). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Sfi Advisors, LLC $527,307 165K 29.8% 0.0%
Vanguard Capital Management LLC $526,273 165K 29.7% ▲ 2.1%
Massmutual Private Wealth & Trust, Fsb $354,202 111K 20.0% 0.0%
Geode Capital Management, LLC $147,651 46K 8.3% ▲ 6.1%
Vanguard Fiduciary Trust Co $74,474 23K 4.2% 0.0%
FMR LLC $63,800 20K 3.6% New
Susquehanna International Group, LLP $44,864 14K 2.5% ▲ 40.4%
Blackrock, Inc. $21,361 7K 1.2% ▼ 52.1%
Osaic Holdings, Inc. $7,975 3K 0.5% 0.0%
Morgan Stanley $1,930 1K 0.1% ▲ 0.7%
UBS Group AG $1,008 0K 0.1% ▼ 53.0%
Barclays PLC $45 0K 0.0% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cryo Cell International Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 21, 2025 estimated from the company's past filing pattern, not announced

  • October 17, 2024
  • February 24, 2022
  • October 15, 2021
  • July 19, 2021
  • April 16, 2021
  • February 25, 2021

Recent SEC filings

Data status

When each part of this page on Cryo Cell International Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Cryo Cell International Inc in brief

What does Cryo Cell International Inc do?
Cryo Cell International Inc is a US-listed company in the health care services industry. Its financial year ends in November.
What is Cryo Cell International Inc's stock ticker?
Cryo Cell International Inc trades under the ticker CCEL on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Cryo Cell International Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Cryo Cell International Inc reported revenue of $31.1M, 2.0% lower than a year earlier, according to its SEC filings.
What is Cryo Cell International Inc's free cash flow?
Cryo Cell International Inc's free-cash-flow margin is 14.9% of revenue over the trailing twelve months, ranking 4 of the 40 health care services companies we cover.
What is Cryo Cell International Inc's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Cryo Cell International Inc's free cash flow after stock-based pay gives ~$9.8 per share in the base case, and ~$7.2–$13 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Cryo Cell International Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Sfi Advisors, LLC, Vanguard Capital Management LLC and Massmutual Private Wealth & Trust, Fsb. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Cryo Cell International Inc buying back stock, and does it pay a dividend?
Cryo Cell International Inc spent $169,502 on share repurchases over the trailing twelve months, and its diluted share count fell 1.4% over the year.
What is Cryo Cell International Inc's market cap?
On November 2, 2026, Cryo Cell International Inc's market capitalisation was about $42.9M and net debt of $7M. Market figures come from third-party market data and may be delayed.
Does Cryo Cell International Inc pay a dividend?
Cryo Cell International Inc reported no dividend payments in its trailing twelve months of filings.
Who are Cryo Cell International Inc's competitors?
In our Health Care Services peer group, the companies closest to Cryo Cell International Inc are American Shared Hospital Services, Haoxi Health Technology Ltd, Akso Health Group, Ridgetech Inc. and NRC Health. The side-by-side comparison below sets their revenue, margins and growth against Cryo Cell International Inc's.